---
title: "Weekly Recap | BEONE MEDICINES -0.37%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300184894.md"
description: "BEONE MEDICINES (6160.HK) slipped 0.37% this week to close at HK$216.4, outperforming the Hang Seng Index’s 2.13% decline by about 1.76 percentage points. The stock opened Monday at HK$219, hit a weekly high of HK$221.4, then pulled back to a low of HK$214 on Wednesday before steadying on Thursday. The weekly range was 3.38%, with trading activity noticeably lighter than the recent median. No major catalyst emerged."
datetime: "2026-09-26T05:37:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300184894.md)
  - [en](https://longbridge.com/en/news/300184894.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300184894.md)
generator: "portal-rs"
---

# Weekly Recap | BEONE MEDICINES -0.37%, most brokers rate it buy

## The Week

BEONE MEDICINES (6160.HK) slipped 0.37% this week to close at HK$216.4, outperforming the Hang Seng Index’s 2.13% decline by about 1.76 percentage points. The stock opened Monday at HK$219, hit a weekly high of HK$221.4, then pulled back to a low of HK$214 on Wednesday before steadying on Thursday. The weekly range was 3.38%, with trading activity noticeably lighter than the recent median. No major catalyst emerged.

## Analyst Ratings

Among the 18 analysts covering the stock, 14 rate it buy, 3 rate it overweight, and 1 rates it hold. The consensus rating is strong buy. The consensus target price is HK$263.542, about 21.8% above the latest close, with targets ranging from HK$226.039 to HK$321.760 — a wide spread. The stock ranks 4th among 52 names in the biotech industry by analyst rating.

## The Week Ahead

Watch whether the pharma sector can maintain its relative strength against a softer broader market. This week’s brief outperformance came alongside falling volumes, suggesting limited conviction; the next move likely depends on fresh industry news or company updates.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)

## Related News & Research

- [BeOne Medicines (ONC) Priority Review And Earnings Put Valuation Back In Focus](https://longbridge.com/en/news/304861942.md)
- [BeOne Medicines Reports Unaudited Third-Quarter 2026 Results](https://longbridge.com/en/news/304446876.md)
- [BeOne Medicines Publishes Clinical Trial Portfolio Presentation](https://longbridge.com/en/news/304441863.md)
- [BREAKINGVIEWS-Biotech rising star has lifeline from geopolitics](https://longbridge.com/en/news/304799087.md)
- [14 companies sold 108,247 Bitcoin in 2026, but here’s why it’s not what it looks like!](https://longbridge.com/en/news/305139945.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**